Proportion of participants cleared or almost cleared ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis
Ustekinumab showed no clear difference in proportion of participants achieving a 50% reduction in disease… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain remission · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in failure to maintain clinical remission compared with placebo (moderate certainty).
2 findings from 1 review
Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission
Ustekinumab probably leads to lower failure to maintain clinical response compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction) · induction of remission in Crohn's disease
Ustekinumab leads to lower failure to induce clinical response CDAI (≥100 point reduction) compared with placebo (high certainty).
1 finding from 1 review
Failure to induce clinical response (6 mg/kg subgroup) CDAI (≥100 point reduction) · induction of remission in Crohn's disease
Ustekinumab leads to lower failure to induce clinical response (6 mg/kg subgroup) CDAI (≥100… compared with placebo (high certainty).
1 finding from 1 review
Adverse events · induction of remission in Crohn's disease
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · induction of remission in Crohn's disease
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · induction of remission in Crohn's disease
Ustekinumab showed no clear difference in withdrawals due to adverse event compared with placebo (low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · induction of remission in Crohn's disease
Ustekinumab leads to lower failure to induce clinical remission CDAI (≤ 150) compared with placebo (high certainty).
2 findings from 1 review